Compare AAP & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | IRON |
|---|---|---|
| Founded | 1929 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | N/A | N/A |
| Metric | AAP | IRON |
|---|---|---|
| Price | $46.23 | $92.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $52.18 | ★ $108.83 |
| AVG Volume (30 Days) | ★ 1.4M | 560.9K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,624,327,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.89 | $30.82 |
| 52 Week High | $70.00 | $99.50 |
| Indicator | AAP | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 55.66 |
| Support Level | $45.45 | $90.40 |
| Resistance Level | $54.73 | $99.50 |
| Average True Range (ATR) | 2.31 | 3.76 |
| MACD | -0.41 | -0.51 |
| Stochastic Oscillator | 8.99 | 38.72 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.